|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Muralidharan-Chari V, Clancy JW, Sedgwick
A and DSouza-Schorey C: Microvesicles: Mediators of extracellular
communication during cancer progression. J Cell Sci. 123:1603–1611.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choy B, Findeis-Hosey JJ, Li F, McMahon
LA, Yang Q and Xu H: High frequency of coexpression of maspin with
p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of
the lung. Int J Clin Exp Pathol. 6:2542–2547. 2013.PubMed/NCBI
|
|
6
|
Fukui T, Taniguchi T, Kawaguchi K,
Fukumoto K, Nakamura S, Sakao Y and Yokoi K: Comparisons of the
clinicopathological features and survival outcomes between lung
cancer patients with adenocarcinoma and squamous cell carcinoma.
Gen Thorac Cardiovasc Surg. 63:507–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Argon A, Nart D and Veral A: The value of
cytokeratin 5/6, p63 and thyroid transcription factor-1 in
adenocarcinoma, squamous cell carcinoma and non-small-cell lung
cancer of the lung. Turk Patoloji Derg. 31:81–88. 2015.PubMed/NCBI
|
|
8
|
Singhal S, Miller D, Ramalingam S and Sun
SY: Gene expression profiling of non-small cell lung cancer. Lung
Cancer. 60:313–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi WY, Liu KD, Xu SG, Zhang JT, Yu LL, Xu
KQ and Zhang TF: Gene expression analysis of lung cancer. Eur Rev
Med Pharmacol Sci. 18:217–228. 2014.PubMed/NCBI
|
|
10
|
Lu C, Chen H, Shan Z and Yang L:
Identification of differentially expressed genes between lung
adenocarcinoma and lung squamous cell carcinoma by gene expression
profiling. Mol Med Rep. 14:1483–1490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lacroix L, Commo F and Soria JC: Gene
expression profiling of non-small-cell lung cancer. Expert Rev Mol
Diagn. 8:167–178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grigoroiu M, Tagett R, Draghici S, Dima S,
Nastase A, Florea R, Sorop A, Ilie V, Bacalbasa N, Tica V, et al:
Gene-expression profiling in non-small cell lung cancer with
invasion of mediastinal lymph nodes for prognosis evaluation.
Cancer Genomics Proteomics. 12:231–242. 2015.PubMed/NCBI
|
|
13
|
Yousef GM, Scorilas A, Nakamura T, Ellatif
MA, Ponzone R, Biglia N, Maggiorotto F, Roagna R, Sismondi P and
Diamandis EP: The prognostic value of the human kallikrein gene 9
(KLK9) in breast cancer. Breast Cancer Res Treat. 78:149–158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bahassi el M and Stambrook PJ:
Next-generation sequencing technologies: Breaking the sound barrier
of human genetics. Mutagenesis. 29:303–310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hagemann IS, Devarakonda S, Lockwood CM,
Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT,
Duncavage EJ, Cottrell CE, et al: Clinical next-generation
sequencing in patients with non-small cell lung cancer. Cancer.
121:631–639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu X, Yang Y, Li H, Chen Z, Jiang G and
Fei K: Assessment of the clinical application of detecting EGFR,
KRAS, PIK3CA and BRAF mutations in patients with non-small cell
lung cancer using next-generation sequencing. Scand J Clin Lab
Invest. 76:386–392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate-a practical and powerful approach to
multiple testing. J R Stat Soc B. 57:289–300. 1995.
|
|
18
|
Wang T, Han P, He Y, Zhao C, Wang G, Yang
W, Shan M, Zhu Y, Yang C, Weng M, et al: Lin28A enhances
chemosensitivity of colon cancer cells to 5-FU by promoting
apoptosis in a let-7 independent manner. Tumour Biol. 37:7657–7665.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen H, Yang Y, Zhao L, Yuan J and Niu Y:
Lin28A and androgen receptor expression in
ER−/Her2+ breast cancer. Breast Cancer Res
Treat. 156:135–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sugano M, Nagasaka T, Sasaki E, Murakami
Y, Hosoda W, Hida T, Mitsudomi T and Yatabe Y: HNF4α as a marker
for invasive mucinous adenocarcinoma of the lung. Am J Surg Pathol.
37:211–218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang Y, Shu G, Yuan X, Jing N and Song J:
FOXA2 functions as a suppressor of tumor metastasis by inhibition
of epithelial-to-mesenchymal transition in human lung cancers. Cell
Res. 21:316–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi
JL, Shao Z, Liang S, Wang LP, Hwang WT, et al: Lin-28 homologue A
(LIN28A) promotes cell cycle progression via regulation of
cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell
division cycle 25 homolog A (CDC25A) expression in cancer. J Biol
Chem. 287:17386–17397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oh JS, Kim JJ, Byun JY and Kim IA:
Lin28-let7 modulates radiosensitivity of human cancer cells with
activation of K-Ras. Int J Radiat Oncol Biol Phys. 76:5–8. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiong H, Zhao W, Wang J, Seifer BJ, Ye C,
Chen Y, Jia Y, Chen C, Shen J, Wang L, et al: Oncogenic mechanisms
of Lin28 in breast cancer: New functions and therapeutic
opportunities. Oncotarget. 8:25721–25735. 2017.PubMed/NCBI
|
|
25
|
Bingle L, Cross SS, High AS, Wallace WA,
Devine DA, Havard S, Campos MA and Bingle CD: SPLUNC1 (PLUNC) is
expressed in glandular tissues of the respiratory tract and in lung
tumours with a glandular phenotype. J Pathol. 205:491–497. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Corfield AP: Mucins: A biologically
relevant glycan barrier in mucosal protection. Biochim Biophys
Acta. 1850:236–252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Palmer M, Parker J, Modi S, Butts C,
Smylie M, Meikle A, Kehoe M, MacLean G and Longenecker M: Phase I
study of the BLP25 (MUC1 peptide) liposomal vaccine for active
specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.
Clin Lung Cancer. 3:49–58. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu L, Wu S, Yang Y, Cai J, Zhu X, Wu J,
Li M and Guan H: SOSTDC1 is down-regulated in non-small cell lung
cancer and contributes to cancer cell proliferation. Cell Biosci.
6:242016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kestler DP, Foster JS, Bruker CT, Prenshaw
JW, Kennel SJ, Wall JS, Weiss DT and Solomon A: ODAM expression
inhibits human breast cancer tumorigenesis. Breast Cancer (Auckl).
5:73–85. 2011.PubMed/NCBI
|
|
30
|
Ishii H, Vecchione A, Murakumo Y,
Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R and Croce CM:
FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates
mitosis. Proc Natl Acad Sci USA. 98:10374–10379. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee MJ, Yu GR, Yoo HJ, Kim JH, Yoon BI,
Choi YK and Kim DG: ANXA8 down-regulation by EGF-FOXO4 signaling is
involved in cell scattering and tumor metastasis of
cholangiocarcinoma. Gastroenterology. 137:1138–1150, 1150.e1-e9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shan Q, Lou X, Xiao T, Zhang J, Sun H, Gao
Y, Cheng S, Wu L, Xu N and Liu S: A cancer/testis antigen
microarray to screen autoantibody biomarkers of non-small cell lung
cancer. Cancer Lett. 328:160–167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Djureinovic D, Hallstrom BM, Horie M,
Mattsson JSM, La Fleur L, Fagerberg L, Brunnström H, Lindskog C,
Madjar K, Rahnenführer J, et al: Profiling cancer testis antigens
in non-small-cell lung cancer. JCI Insight. 1:e868372016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zendman AJ, Van Kraats AA, Weidle UH,
Ruiter DJ and Van Muijen GN: The XAGE family of
cancer/testis-associated genes: Alignment and expression profile in
normal tissues, melanoma lesions and Ewings sarcoma. Int J Cancer.
99:361–369. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hellerbrand C, Amann T, Schlegel J, Wild
P, Bataille F, Spruss T, Hartmann A and Bosserhoff AK: The novel
gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma.
Gut. 57:243–251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lind GE, Skotheim RI, Fraga MF, Abeler VM,
Esteller M and Lothe RA: Novel epigenetically deregulated genes in
testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J
Pathol. 210:441–449. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
SantAnna-Silva ACB, Santos GC, Campos SPC,
Oliveira Gomes AM, Perez-Valencia JA and Rumjanek FD: Metabolic
profile of oral squamous carcinoma cell lines relies on a higher
demand of lipid metabolism in metastatic cells. Front Oncol.
8:132018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Long J, Zhang CJ, Zhu N, Du K, Yin YF, Tan
X, Liao DF and Qin L: Lipid metabolism and carcinogenesis, cancer
development. Am J Cancer Res. 8:778–791. 2018.PubMed/NCBI
|
|
39
|
Luo X, Cheng C, Tan Z, Li N, Tang M, Yang
L and Cao Y: Emerging roles of lipid metabolism in cancer
metastasis. Mol Cancer. 16:762017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo JY and White E: Autophagy is required
for mitochondrial function, lipid metabolism, growth, and fate of
KRAS (G12D)-driven lung tumors. Autophagy. 9:1636–1638. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Murray GI, Taylor MC, McFadyen MC, McKay
JA, Greenlee WF, Burke MD and Melvin WT: Tumor-specific expression
of cytochrome P450 CYP1B1. Cancer Res. 57:3026–3031.
1997.PubMed/NCBI
|
|
42
|
Su JM, Lin P, Wang CK and Chang H:
Overexpression of cytochrome P450 1B1 in advanced non-small cell
lung cancer: A potential therapeutic target. Anticancer Res.
29:509–515. 2009.PubMed/NCBI
|
|
43
|
Chen ZH, Hurh YJ, Na HK, Kim JH, Chun YJ,
Kim DH, Kang KS, Cho MH and Surh YJ: Resveratrol inhibits
TCDD-induced expression of CYP1A1 and CYP1B1 and catechol
estrogen-mediated oxidative DNA damage in cultured human mammary
epithelial cells. Carcinogenesis. 25:2005–2013. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wen X, Walle UK and Walle T:
5,7-Dimethoxyflavone downregulates CYP1A1 expression and
benzo[a]pyrene-induced DNA binding in Hep G2 cells. Carcinogenesis.
26:803–809. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qiao E, Ji M, Wu J, Ma R, Zhang X, He Y,
Zha Q, Song X, Zhu LW and Tang J: Expression of the PXR gene in
various types of cancer and drug resistance. Oncol Lett.
5:1093–1100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xue P, Fu J and Zhou Y: The aryl
hydrocarbon receptor and tumor immunity. Front Immunol. 9:2862018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Swales KE, Korbonits M, Carpenter R, Walsh
DT, Warner TD and Bishop-Bailey D: The farnesoid X receptor is
expressed in breast cancer and regulates apoptosis and aromatase
expression. Cancer Res. 66:10120–10126. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang F, Huang X, Yi T, Yen Y, Moore DD and
Huang W: Spontaneous development of liver tumors in the absence of
the bile acid receptor farnesoid X receptor. Cancer Res.
67:863–867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Guan B, Li H, Yang Z, Hoque A and Xu X:
Inhibition of farnesoid X receptor controls esophageal cancer cell
growth in vitro and in nude mouse xenografts. Cancer.
119:1321–1329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fukuchi J, Kokontis JM, Hiipakka RA, Chuu
CP and Liao S: Antiproliferative effect of liver X receptor
agonists on LNCaP human prostate cancer cells. Cancer Res.
64:7686–7689. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Khuri FR, Lotan R, Kemp BL, Lippman SM, Wu
H, Feng L, Lee JJ, Cooksley CS, Parr B, Chang E, et al: Retinoic
acid receptor-beta as a prognostic indicator in stage I
non-small-cell lung cancer. J Clin Oncol. 18:2798–2804. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chang YS, Chung JH, Shin DH, Chung KY, Kim
YS, Chang J and Kim SK and Kim SK: Retinoic acid receptor-beta
expression in stage I non-small cell lung cancer and adjacent
normal appearing bronchial epithelium. Yonsei Med J. 45:435–442.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang J, Zhang J, Xu L, Zheng Y, Ling D and
Yang Z: Expression of HNF4G and its potential functions in lung
cancer. Oncotarget. 9:18018–18028. 2017.PubMed/NCBI
|
|
54
|
Bell EH, Chakraborty AR, Mo X, Liu Z,
Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R,
et al: SMARCA4/BRG1 is a novel prognostic biomarker predictive of
cisplatin-based chemotherapy outcomes in resected non-small cell
lung cancer. Clin Cancer Res. 22:2396–2404. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Guerrero-Martinez JA and Reyes JC: High
expression of SMARCA4 or SMARCA2 is frequently associated with an
opposite prognosis in cancer. Sci Rep. 8:20432018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kulkarni AA, Thatcher TH, Olsen KC,
Maggirwar SB, Phipps RP and Sime PJ: PPAR-γ ligands repress
TGFβ-induced myofibroblast differentiation by targeting the
PI3K/Akt pathway: Implications for therapy of fibrosis. PLoS One.
6:e159092011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Elnemr A, Ohta T, Iwata K, Ninomia I,
Fushida S, Nishimura G, Kitagawa H, Kayahara M, Yamamoto M, Terada
T and Miwa K: PPARgamma ligand (thiazolidinedione) induces growth
arrest and differentiation markers of human pancreatic cancer
cells. Int J Oncol. 17:1157–1164. 2000.PubMed/NCBI
|
|
58
|
Ogino S, Shima K, Baba Y, Nosho K, Irahara
N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, et al: Colorectal
cancer expression of peroxisome proliferator-activated receptor
gamma (PPARG, PPARgamma) is associated with good prognosis.
Gastroenterology. 136:1242–1250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yuan H, Kopelovich L, Yin Y, Lu J and
Glazer RI: Drug-targeted inhibition of peroxisome
proliferator-activated receptor-gamma enhances the chemopreventive
effect of anti-estrogen therapy. Oncotarget. 3:345–356. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Srinivas H, Juroske DM, Kalyankrishna S,
Cody DD, Price RE, Xu XC, Narayanan R, Weigel NL and Kurie JM:
c-Jun N-terminal kinase contributes to aberrant retinoid signaling
in lung cancer cells by phosphorylating and inducing proteasomal
degradation of retinoic acid receptor alpha. Mol Cell Biol.
25:1054–1069. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Szabo E, Riffe ME, Steinberg SM, Birrer MJ
and Linnoila RI: Altered cJUN expression: An early event in human
lung carcinogenesis. Cancer Res. 56:305–315. 1996.PubMed/NCBI
|
|
62
|
Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino
U, Pilotti S, Kurie JM, Hong WK and Lotan R: Suppression of
retinoic acid receptor beta in non-small-cell lung cancer in vivo:
Implications for lung cancer development. J Natl Cancer Inst.
89:624–629. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dai J, Punchihewa C, Mistry P, Ooi AT and
Yang D: Novel DNA bis-intercalation by MLN944, a potent clinical
bisphenazine anticancer drug. J Biol Chem. 279:46096–46103. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Marquez-Garban DC, Chen HW, Fishbein MC,
Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in
human non-small cell lung cancer. Steroids. 72:135–143. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Borczuk AC, Gorenstein L, Walter KL,
Assaad AA, Wang L and Powell CA: Non-small-cell lung cancer
molecular signatures recapitulate lung developmental pathways. Am J
Pathol. 163:1949–1960. 2003. View Article : Google Scholar : PubMed/NCBI
|
